EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Left Atrial Appendage Occlusion in Patients With Hypertrophic Cardiomyopathy, Rheumatic Heart Disease, and Cardiac Amyloidosis

Mohamad S Alabdaljabar, Abdullah Al-Abcha, Mohamad Alkhouli, Benjamin Hibbert, Xiaoke Ken Liu, Trevor Simard, Holly Van Houten, Xiaoxi Yao, Freddy Del-Carpio Munoz, Rowlens M Melduni, Peter A Noseworthy, David R Rushlow und 2 weitere

JACC: Clinical Electrophysiology · 2026

DOI: 10.1016/j.jacep.2025.12.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026. Verfasst von Mohamad S Alabdaljabar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Left Atrial Appendage Closure, Amyloidosis, Rheumatic Heart Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Left atrial appendage occlusion (LAAO) has emerged as an effective stroke- prevention strategy for selected patients with nonvalvular atrial fibrillation (NVAF). However, LAAO outcomes data in patients with hypertrophic cardiomyopathy (HCM), rheumatic heart disease (RHD), or cardiac amyloidosis (CA), are limited. OBJECTIVES: This study aimed to compare the safety and efficacy of LAAO in patients with NVAF, with and without comorbid HCM, RHD, or CA. METHODS: Using OptumLabs Data Warehouse, a retrospective cohort of adult patients undergoing LAAO (2015-2023) was analyzed. Outcomes included mortality, stroke/transient ischemic attack (TIA), and bleeding, with multivariable Cox models and subgroup analyses. RESULTS: A total of 14,755 patients (mean age 76.5 ± 7.0, 43.7% female, median follow-up 1.4 [0.8-2.4] years) were included. Compared with patients with AF, patients AF + RHD had high risk of nongastrointestinal/intracranial bleeding events (HR: 1.24; 95% CI: 1.04-1.49; P = 0.02), whereas AF + CA showed higher risk of composite endpoint (mortality, stroke/TIA, bleeding) (HR: 1.63; 95% CI: 1.17-2.27; P = 0.004), stroke/TIA (HR: 2.00; 95% CI; 1.13-3.54; P = 0.02), and gastrointestinal bleeding (HR: 2.50; 95% CI: 1.14-5.47; P = 0.02). There were no significant differences in clinical outcomes between patients with AF alone and those with AF + HCM. CONCLUSIONS: Patients with AF and either RHD or CA experienced higher bleeding rates following LAAO compared with those without these conditions, despite similar stroke/TIA rates in AF + RHD, suggesting a higher inherent bleeding risk and possibly further supporting a role of LAAO. Importantly, there was no difference in outcomes between patients with AF and HCM vs those without. Because of the small sample size, the results in HCM and CA cohorts are mainly hypothesis generating.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicLeft Atrial Appendage ClosureAmyloidosisRheumatic Heart DiseaseAtrial FibrillationAtrial AppendageHumansFemaleMaleRetrospective StudiesAgedTreatment OutcomeStrokeAged, 80 and overIschemic Attack, Transient

Stichwörter der Autor:innen

atrial fibrillationcardiac amyloidosishypertrophic cardiomyopathyleft atrial appendage occlusionrheumatic heart disease

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA; OptumLabs, Eden Prairie, Minnesota, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA.
  • Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: killu.ammar@mayo.edu.

Zitieren

APA

Alabdaljabar, M. S., Al-Abcha, A., Alkhouli, M., Hibbert, B., Liu, X. K., Simard, T., Van Houten, H., Yao, X., Del-Carpio Munoz, F., Melduni, R. M., Noseworthy, P. A., Rushlow, D. R., Friedman, P., & Killu, A. M. (2026). Outcomes of Left Atrial Appendage Occlusion in Patients With Hypertrophic Cardiomyopathy, Rheumatic Heart Disease, and Cardiac Amyloidosis. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2025.12.019

Vancouver

Alabdaljabar MS, Al-Abcha A, Alkhouli M, Hibbert B, Liu XK, Simard T, et al. Outcomes of Left Atrial Appendage Occlusion in Patients With Hypertrophic Cardiomyopathy, Rheumatic Heart Disease, and Cardiac Amyloidosis. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2025.12.019

BibTeX
@article{Alabdaljabar2026,
  author = {Alabdaljabar, Mohamad S and Al-Abcha, Abdullah and Alkhouli, Mohamad and Hibbert, Benjamin and Liu, Xiaoke Ken and Simard, Trevor and Van Houten, Holly and Yao, Xiaoxi and Del-Carpio Munoz, Freddy and Melduni, Rowlens M and Noseworthy, Peter A and Rushlow, David R and Friedman, Paul and Killu, Ammar M},
  title = {Outcomes of Left Atrial Appendage Occlusion in Patients With Hypertrophic Cardiomyopathy, Rheumatic Heart Disease, and Cardiac Amyloidosis},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  doi = {10.1016/j.jacep.2025.12.019}
}
Kostenlos starten →